Guangquan Zhang, Shiyi Zhu, Zhi-yong Ji, Pei-quan Zhou, Shancai Xu, Huaizhang Shi
{"title":"脑过度灌注综合征的研究进展","authors":"Guangquan Zhang, Shiyi Zhu, Zhi-yong Ji, Pei-quan Zhou, Shancai Xu, Huaizhang Shi","doi":"10.3969/CJCNN.V17I12.1701","DOIUrl":null,"url":null,"abstract":"Cerebral hyperperfusion syndrome (CHS) is a rare syndrome deriving from carotid endovascular treatment with a high mortality. CHS can be derived by carotid endarterectomy (CEA), carotid artery stenting (CAS) and intracranial artery stenting. This review aims to summarize the progress of clinical manifestations, risk factors, pathogenesis, diagnostic criteria, prevention and treatment for CHS in recent years. DOI: 10.3969/j.issn.1672-6731.2017.12.003","PeriodicalId":10113,"journal":{"name":"中国现代神经疾病杂志","volume":"17 1","pages":"869-873"},"PeriodicalIF":0.0000,"publicationDate":"2017-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Research progress of cerebral hyperperfusion syndrome\",\"authors\":\"Guangquan Zhang, Shiyi Zhu, Zhi-yong Ji, Pei-quan Zhou, Shancai Xu, Huaizhang Shi\",\"doi\":\"10.3969/CJCNN.V17I12.1701\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cerebral hyperperfusion syndrome (CHS) is a rare syndrome deriving from carotid endovascular treatment with a high mortality. CHS can be derived by carotid endarterectomy (CEA), carotid artery stenting (CAS) and intracranial artery stenting. This review aims to summarize the progress of clinical manifestations, risk factors, pathogenesis, diagnostic criteria, prevention and treatment for CHS in recent years. DOI: 10.3969/j.issn.1672-6731.2017.12.003\",\"PeriodicalId\":10113,\"journal\":{\"name\":\"中国现代神经疾病杂志\",\"volume\":\"17 1\",\"pages\":\"869-873\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-12-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国现代神经疾病杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3969/CJCNN.V17I12.1701\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国现代神经疾病杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3969/CJCNN.V17I12.1701","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Research progress of cerebral hyperperfusion syndrome
Cerebral hyperperfusion syndrome (CHS) is a rare syndrome deriving from carotid endovascular treatment with a high mortality. CHS can be derived by carotid endarterectomy (CEA), carotid artery stenting (CAS) and intracranial artery stenting. This review aims to summarize the progress of clinical manifestations, risk factors, pathogenesis, diagnostic criteria, prevention and treatment for CHS in recent years. DOI: 10.3969/j.issn.1672-6731.2017.12.003
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
